AI Biomed PredictionsMAIA – Late-Stage NSCLC Progress Could Reawaken MAIA’s Microcap Upside ScanScor Admin / May 31, 2026
AI Biomed PredictionsAVIR – Phase 3 HCV data could decide Atea’s next rerating ScanScor Admin / May 20, 2026
AI Biomed PredictionsNGEN – NervGen’s next rerating likely hinges on 2Q clinical follow-through ScanScor Admin / May 10, 2026
AI Biomed PredictionsNMRA – Phase 3 Redemption Window Nears for Beaten-Down Neumora Shares ScanScor Admin / May 10, 2026
AI Biomed PredictionsHIND – Phase 3 clarity could awaken this forgotten microcap biotech ScanScor Admin / April 30, 2026
AI Biomed PredictionsCVKD – Phase 3 clarity could revive battered microcap HIT story ScanScor Admin / April 17, 2026
